Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SGLT2 inhibitor effects on renal prognosis in chronic kidney disease with type 2 diabetes
ChiCTR2000036769Phase 4Recruiting
- Sponsor
- Ruijin Hospital
- Start
- Sep 2020
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of dapagliflozin and liraglutide in diabetic glomerulosclerosis, chronic kidney disease (CKD) and type 2 diabetes mellitus (T2DM) (3 arms), sponsored by Ruijin Hospital. Primary endpoint: Serum creatinine. Started Sep 2020; status: recruiting.
02
Drugs
dapagliflozinliraglutide
03
Conditions
diabetic glomerulosclerosischronic kidney disease (CKD)type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on ChiCTR2000036769.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000036769.